Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics, Inc. (NASDAQ: MYGN) generates frequent news as a molecular diagnostic testing and precision medicine company. Its announcements often cover financial results, clinical research, product updates, and collaborations that shape how genetic and genomic testing is used in oncology, women’s health, and mental health care.
Investors and clinicians following MYGN news will see regular earnings releases and financial guidance updates, which the company also furnishes on Form 8-K. These updates describe trends in hereditary cancer testing, tumor profiling, prenatal screening, and pharmacogenomics, along with commentary on business performance and strategic priorities.
Scientific and medical conference activity is another major source of news. Myriad Genetics frequently reports new data on tests such as the MyRisk Hereditary Cancer Test, Precise MRD, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, Foresight Carrier Screen, and the GeneSight Psychotropic test. Company communications highlight abstracts and posters at meetings like the San Antonio Breast Cancer Symposium and the National Society of Genetic Counselors Annual Conference.
News items also describe collaborations with partners including SOPHiA GENETICS, Clairity, and MagView, focused on areas such as liquid biopsy companion diagnostics and integrated breast cancer risk assessment platforms. Updates on leadership changes, credit facilities, and conference presentations at investor healthcare events are also part of the MYGN news flow.
This page provides a centralized view of these developments so readers can review Myriad Genetics’ latest financial disclosures, research milestones, product enhancements, and partnership announcements in one place.
Myriad Genetics, a leader in genetic testing and precision medicine, announced its participation in two major healthcare conferences. On Feb. 17, 2022, CFO R. Bryan Riggsbee will engage in a fireside chat at the virtual BTIG MedTech Conference at 12 p.m. ET. This will be followed by a discussion featuring President and CEO Paul J. Diaz and Riggsbee at the SVB Leerink Global Healthcare Conference on Feb. 18, 2022, at 11:20 a.m. ET. Interested parties can access live webcasts of these events via Myriad's investor information section at www.myriad.com.
On January 11, 2022, Paul J. Diaz, President and CEO of Myriad Genetics (NASDAQ: MYGN), will present at the 40th Annual J.P. Morgan Health Care Conference. The presentation, set for 2:15 p.m. ET, will focus on the company’s strategic transformation and growth plans. Diaz will highlight the increasing importance of genetic insights in healthcare, discussing new products that enhance health equity and improve disease detection and treatment. A live audio webcast of the event will be available through Myriad's website and other platforms.
Myriad Genetics announced the retirement of Jerry Lanchbury, Ph.D., as Chief Scientific Officer after over 19 years. A national search for his permanent successor is underway, with Lanchbury providing consulting services until the end of Q1 2022. Dale Muzzey, Ph.D., is promoted to Senior Vice President for Research and Development and will serve as interim CSO. The company emphasizes its commitment to scientific innovation and commercial capabilities during this transition. Myriad Genetics continues to lead in genetic testing and precision medicine.
Summary not available.
Myriad Genetics (NASDAQ: MYGN) has appointed Nicole Lambert as the new Chief Operating Officer. Lambert, with 20 years at Myriad, previously led the Oncology, Women’s Health, and International units. In her expanded role, she aims to enhance operational efficiencies and drive the company’s transformation and growth strategy. CEO Paul J. Diaz highlighted her leadership and experience in improving patient outcomes. Lambert is dedicated to operational excellence and accessibility in genetic testing. The company continues to focus on advancing health through genetic insights.
Summary not available.
Myriad Genetics (NASDAQ: MYGN) announced two poster presentations at the 2021 San Antonio Breast Cancer Symposium (SABCS) underscoring genetic testing's role in breast cancer treatment and risk assessment. The studies focus on genomic instability scores for PARP inhibitor eligibility and enhancing polygenic risk scores to reduce ancestral bias. Key collaborations include Mayo Clinic and Johns Hopkins. These efforts aim to improve equitable care for women with breast cancer, showcasing Myriad's commitment to integrating scientific research into clinical practice.
Myriad Genetics reported financial results for Q3 2021, with total revenue of $167.3 million, a 15% increase year-over-year. Excluding divested businesses, revenue grew by 27%. Diluted GAAP earnings per share (EPS) were $0.30, while adjusted EPS was $(0.02). Diagnostic test volumes rose to 252,000, a 15% year-over-year growth, driven by increases in prenatal and pharmacogenomics tests. Challenges included flat hereditary cancer volumes and sequential declines in some areas. The company ended the quarter with $413.6 million in cash and noted ongoing strategic transformations.
Myriad Genetics, Inc. (NASDAQ: MYGN) will hold its quarterly earnings conference call on November 2, 2021, at 4:30 p.m. EDT, discussing results for the quarter ending September 30, 2021. A financial overview will be presented by Paul J. Diaz, president and CEO, alongside R. Bryan Riggsbee, CFO. Earnings will be released prior to the market opening. Callers can join via a specific dial-in number, and a replay will be available afterward. The live webcast will be accessible on Myriad’s website.
Myriad Genetics announced the appointment of Pamela Wong as the new Chief Legal Officer, effective October 18, 2021. Wong, bringing over 20 years of experience in healthcare and legal sectors, will oversee legal functions including intellectual property, litigation, and regulatory compliance. Her previous roles include serving as Assistant General Counsel at Quest Diagnostics and an intellectual property partner at Baker-McKenzie. CEO Paul J. Diaz praised her expertise, stating she will significantly contribute to the company’s legal strategy and growth initiatives.